EHA 2019 | What is the clinical value of new drugs in AML?
At the 24th Congress of the European Hematology Association (EHA), Gert Ossenkoppele from the UMC Amsterdam, Netherlands (NL), talks about the clinical value of new drugs in acute myeloid leukemia (AML).
Prof. Ossenkoppele stated these are exciting times for hematologists working in the AML field. Novel drugs, gilteritinib and quizartinib, were highlighted as potential options to meet an urgent medial of relapsed/refractory AML, as was venetoclax which was described by Prof. Ossenkoppele as "a game changer" in AML. Venetoclax has mostly been tested in unfit, elderly patients with promising data leading to its approval by the US FDA. Prof. Ossenkoppele hopes this will follow soon in Europe.
Additionally, new combinations with venetoclax are being investigated and this is expected to change the field of AML treatment "extremely soon".